AR085637A1 - Derivados de pirido[2,3-b]pirazina - Google Patents
Derivados de pirido[2,3-b]pirazinaInfo
- Publication number
- AR085637A1 AR085637A1 ARP120100764A ARP120100764A AR085637A1 AR 085637 A1 AR085637 A1 AR 085637A1 AR P120100764 A ARP120100764 A AR P120100764A AR P120100764 A ARP120100764 A AR P120100764A AR 085637 A1 AR085637 A1 AR 085637A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyy
- nyy
- denotes
- het3
- het2
- Prior art date
Links
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091005682 Receptor kinases Proteins 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Uso de tales compuestos, en donde la inhibición, regulación y/o modulación de la transducción de señales por proteínas que consumen ATP como quinasas desempeña un papel importante, en particular a inhibidores de las quinasas TGF-b receptoras y uso de tales compuestos para el tratamiento de enfermedades inducidas por quinasas, en particular para el tratamiento de tumores.Reivindicación 1: Compuestos de la fórmula (1), en donde: X denota ausencia, NR4 o CR5R6; R1 denota arilo monocíclico C3-8 o un heteroarilo monocíclico C1-8 y 1, 2, 3, 4 ó 5 átomos de N, O y/o S, cada uno de los cuales puede estar sustituido, de modo independiente ente sí, con al menos un sustituyente seleccionado del grupo que consiste en Y, Hal, CN, CF3, OY; R2 denota H, A, -OY, -NH2 o -NAA; R3 denota H, A, -OY o -NYY; R4, R5, R6 denotan, de modo independiente entre sí, ausencia, H, A; R7 denota Hal, A, -(CYY)n-OY, -(CYY)n-NYY, (CYY)n-Het2, (CYY)n-O-Het2, SY, NO2, CN, COOY, -CO-NYY, -NY-COA, -NY-SO2A, -SO2-NYY, S(O)mA, -CO-Het2, -O(CYY)n-NYY, -O(CYY)n-Het2, -NH-COOA, -NH-CO-NYY, -NH-COO-(CYY)n-NYY, -NH-COO-(CYY)nHet2, -NH-CO-NH-(CYY)n-NYY, -NH-CO-NH(CYY)n-Het2, -OCO-NH-(CYY)n-NYY, -OCO-NH-(CYY)n-Het2, CHO, COA, =S, =NY, =O; Y denota H o A; A denota alquilo no ramificado o ramificado C1-10, en donde 1, 2, 3, 4, 5, 6 ó 7 átomos de H se pueden reemplazar, de modo independiente entre sí, por Hal y/o en donde uno o dos grupos CH2 pueden estar reemplazados, de modo independiente entre sí, por un O, S, SO, SO2, un grupo -CY=CY- y/o un grupo -CºC- o denota alquilo cíclico C3-7; Het denota un heterociclo mono-, bi- o tricíclico saturado o insaturado C3-20 y 1, 2, 3, 4 ó 5 átomos de N, O y/o S, que puede estar sustituido, de modo independiente entre sí, con al menos un sustituyente R7; Het2 denota un heterociclo mono-, bi- o tricíclico saturado o insaturado C3-20 y 1, 2, 3, 4 ó 5 átomos de N, O y/o S, que puede estar sustituido, de modo independiente entre sí, con al menos un sustituyente seleccionado del grupo de Hal, A, -(CYY)n-OY, -(CYY)n-NYY, (CYY)n-Het3, (CYY)n-O-Het3, SY, NO2, CN, COOY, -CO-NYY, -NY-COA, -NY-SO2A, SO2-NYY, S(O)mA, -CO-Het3, -O(CYY)n-NYY, -O(CYY)n-Het3, -NH-COOA, -NH-CO-NYY, -NH-COO-(CYY)n-NYY, -NH-COO-(CYY)n-Het3, -NH-CO-NH-(CYY)n-NYY, -NH-CO-NH(CYY)-Het3, -OCO-NH-(CYY)n-NYY, -OCO-NH-(CYY)n-Het3, CHO, COA, =S, =NY, =O; Het3 denota un heterociclo mono-, bi- o tricíclico saturado o insaturado C3-20 y 1, 2, 3, 4 ó 5 átomos de N, O y/o S, que puede estar sustituido, de modo independiente entre sí, con al menos un sustituyente seleccionado del grupo de Hal, A, -(CYY)n-OY, -(CYY)n-NYY, SY, NO2, CN, COOY,-CO-NYY, -NY-COA, -NY-SO2A, -SO2-NYY, S(O)mA, -NH-COOA, -NH-CO-NYY, CHO, COA, =S, =NY, =O; Hal denota F, Cl, Br o I; m denota 0, 1 ó 2; n denota 0, 1, 2, 3 ó 4; y sus sales, solvatos, tautómeros y estereoisómeros fisiológicamente aceptables, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11001944 | 2011-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085637A1 true AR085637A1 (es) | 2013-10-16 |
Family
ID=45607719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100764A AR085637A1 (es) | 2011-03-09 | 2012-03-09 | Derivados de pirido[2,3-b]pirazina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9051318B2 (es) |
| EP (1) | EP2683715B1 (es) |
| JP (1) | JP6104824B2 (es) |
| KR (1) | KR20140022829A (es) |
| CN (1) | CN103391938B (es) |
| AR (1) | AR085637A1 (es) |
| AU (1) | AU2012224979B2 (es) |
| BR (1) | BR112013022948A2 (es) |
| CA (1) | CA2829287C (es) |
| EA (1) | EA201300997A1 (es) |
| ES (1) | ES2542647T3 (es) |
| IL (1) | IL228265A (es) |
| MX (1) | MX2013010163A (es) |
| SG (1) | SG193301A1 (es) |
| WO (1) | WO2012119690A1 (es) |
| ZA (1) | ZA201307511B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012224979B2 (en) * | 2011-03-09 | 2017-01-19 | Merck Patent Gmbh | Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses |
| WO2015103355A1 (en) | 2014-01-01 | 2015-07-09 | Medivation Technologies, Inc. | Compounds and methods of use |
| ES2759240T3 (es) * | 2014-04-08 | 2020-05-08 | Rigel Pharmaceuticals Inc | Compuestos de piridina 2,3-disustituidos como inhibidores de TGF-beta |
| US10336761B2 (en) * | 2015-07-23 | 2019-07-02 | Bristol-Myers Squibb Company | TGFβ receptor antagonist |
| EP3692144A1 (en) | 2017-10-05 | 2020-08-12 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CN109053598B (zh) * | 2018-06-14 | 2021-04-13 | 温州大学 | 一种芳基取代喹唑啉化合物及其合成方法 |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| KR20230041003A (ko) * | 2020-07-15 | 2023-03-23 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리도 옥사진 아미노 유도체 |
| CN114149410B (zh) * | 2020-09-07 | 2025-02-25 | 四川科伦博泰生物医药股份有限公司 | 吡啶并环类化合物及其制备方法和用途 |
| GB202016710D0 (en) * | 2020-10-21 | 2020-12-02 | Univ Birmingham | Treatment of eye conditions |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2025072384A1 (en) * | 2023-09-28 | 2025-04-03 | Purdue Research Foundation | 5/6-5/6-bisaryl compounds as tak1 inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042461A1 (en) | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| AU4972900A (en) | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
| US20040038856A1 (en) | 2002-05-17 | 2004-02-26 | Sarvajit Chakravarty | Treatment of fibroproliferative disorders using TGF-beta inhibitors |
| EP1575506A4 (en) | 2002-07-25 | 2008-04-23 | Scios Inc | METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS |
| WO2004081009A1 (en) * | 2003-03-12 | 2004-09-23 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
| TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| US20070105865A1 (en) | 2003-09-09 | 2007-05-10 | Neurogen Corporation | Substituted bicyclic quinazolin-4-ylamine derivatives |
| JP2007509985A (ja) | 2003-10-31 | 2007-04-19 | ニューロジェン・コーポレーション | カプサイシン受容体作動薬 |
| BRPI0417213A (pt) | 2003-12-24 | 2007-02-06 | Scios Inc | tratamento de gliomas malìgnos com inibidores de tgf-beta |
| TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
| WO2006076646A2 (en) | 2005-01-14 | 2006-07-20 | Neurogen Corporation | Heteroaryl substituted quinolin-4-ylamine analogues |
| BRPI0619424B1 (pt) | 2005-12-05 | 2022-02-08 | Pfizer Products Inc | Uso de inibidores c-met/hgfrs para a fabricação de medicamentos |
| EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| JP4751856B2 (ja) | 2007-07-03 | 2011-08-17 | 本田技研工業株式会社 | 車体側部構造 |
| GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010052448A2 (en) * | 2008-11-05 | 2010-05-14 | Ucb Pharma S.A. | Fused pyrazine derivatives as kinase inhibitors |
| CA2750051A1 (en) | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| AU2012224979B2 (en) * | 2011-03-09 | 2017-01-19 | Merck Patent Gmbh | Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses |
-
2012
- 2012-02-13 AU AU2012224979A patent/AU2012224979B2/en not_active Ceased
- 2012-02-13 SG SG2013066550A patent/SG193301A1/en unknown
- 2012-02-13 CN CN201280010974.7A patent/CN103391938B/zh not_active Expired - Fee Related
- 2012-02-13 JP JP2013556989A patent/JP6104824B2/ja not_active Expired - Fee Related
- 2012-02-13 MX MX2013010163A patent/MX2013010163A/es not_active Application Discontinuation
- 2012-02-13 EA EA201300997A patent/EA201300997A1/ru unknown
- 2012-02-13 KR KR1020137026431A patent/KR20140022829A/ko not_active Withdrawn
- 2012-02-13 ES ES12704233.1T patent/ES2542647T3/es active Active
- 2012-02-13 EP EP12704233.1A patent/EP2683715B1/en not_active Not-in-force
- 2012-02-13 BR BR112013022948A patent/BR112013022948A2/pt not_active Application Discontinuation
- 2012-02-13 CA CA2829287A patent/CA2829287C/en not_active Expired - Fee Related
- 2012-02-13 US US14/002,991 patent/US9051318B2/en not_active Expired - Fee Related
- 2012-02-13 WO PCT/EP2012/000630 patent/WO2012119690A1/en not_active Ceased
- 2012-03-09 AR ARP120100764A patent/AR085637A1/es not_active Application Discontinuation
-
2013
- 2013-09-03 IL IL228265A patent/IL228265A/en active IP Right Grant
- 2013-10-08 ZA ZA2013/07511A patent/ZA201307511B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012224979A1 (en) | 2013-10-24 |
| WO2012119690A1 (en) | 2012-09-13 |
| CA2829287C (en) | 2019-12-17 |
| SG193301A1 (en) | 2013-10-30 |
| KR20140022829A (ko) | 2014-02-25 |
| CN103391938A (zh) | 2013-11-13 |
| US20130345227A1 (en) | 2013-12-26 |
| ES2542647T3 (es) | 2015-08-07 |
| MX2013010163A (es) | 2013-10-30 |
| EA201300997A1 (ru) | 2014-02-28 |
| JP6104824B2 (ja) | 2017-03-29 |
| IL228265A0 (en) | 2013-11-25 |
| CN103391938B (zh) | 2016-02-24 |
| BR112013022948A2 (pt) | 2016-12-06 |
| AU2012224979B2 (en) | 2017-01-19 |
| EP2683715B1 (en) | 2015-04-15 |
| EP2683715A1 (en) | 2014-01-15 |
| US9051318B2 (en) | 2015-06-09 |
| JP2014511390A (ja) | 2014-05-15 |
| IL228265A (en) | 2016-12-29 |
| CA2829287A1 (en) | 2012-09-13 |
| ZA201307511B (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085637A1 (es) | Derivados de pirido[2,3-b]pirazina | |
| AR082109A1 (es) | Derivados de bipiridilo | |
| AR081994A1 (es) | Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| AR072622A1 (es) | Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR082726A1 (es) | Derivados de triazolopirazina | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR064635A1 (es) | Derivados de benzotiazolona | |
| CO6210701A2 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico | |
| AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR067648A1 (es) | Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |